ArticleTransfusion2026
A survey of transfusion support strategies for passenger lymphocyte syndrome in minor ABO-mismatched allogeneic hematopoietic stem cell transplantation.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPassenger lymphocyte syndrome (PLS) is a hematologic complication of ABO blood-type minor incompatibility that can occur following both solid-organ and hematopoietic stem cell transplant (HSCT). HSCT patients usually require red blood cell (RBC) transfusions until they achieve full erythroid engraftment. It is unclear whether the blood bank should honor the recipient's blood type or the donor's blood type at the time of issuing RBC products for minor ABO-incompatible HSCT patients prior to full engraftment. To avoid this confusion, blood group O RBCs are often transfused. However, the role of this approach in the prevention of PLS in minor ABO-mismatched HSCT recipients prior to full engraftment is not well understood. STUDY DESIGN AND
methodsWe conducted a survey of academic hospital blood banks across the United States in October-December 2025 to assess their practices for providing RBC transfusion support to minor-incompatible HSCT patients.
resultsSixteen out of 24 hospital blood banks, including adult and pediatric centers, responded to the survey. The majority reported providing crossmatch-compatible type O RBC to recipients with blood types A, B, or AB, regardless of engraftment outcome. Five do not routinely transfuse O RBC. Two hospitals had one patient each with PLS resulting in severe intravascular hemolysis, and 11 reported mild PLS despite providing crossmatch-compatible type O RBC products to recipients.
conclusionRegardless of the blood type of the transfused RBC, mild PLS can occur in minor ABO-incompatible HSCT patients prior to full engraftment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.